产品说明书

Paquinimod

Print
Chemical Structure| 248282-01-1 同义名 : ABR 25757;ABR-215757;ABR‑215757
CAS号 : 248282-01-1
货号 : A525721
分子式 : C21H22N2O3
纯度 : 99%+
分子量 : 350.411
MDL号 : MFCD18633277
存储条件：

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 60 mg/mL(171.23 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Paquinimod, also known as ABR 215757, is a targeted and orally administered inhibitor of S100A8/S100A9. It effectively alleviates pneumonia and significantly lowers viral counts in mice infected with SARS-CoV-2[1][2][3].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01487551 Systemic Sclerosis Phase 2 Completed - Germany ... 展开 >> Berlin, Germany Cologne, Germany Erlangen, Germany Sweden Gothenburg, Sweden Lund, Sweden Switzerland Zürich, Switzerland 收起 <<
NCT00997100 Systemic Lupus Erythematosus Phase 2 Completed - Denmark ... 展开 >> Soren Jacobsen Copenhagen, Denmark, 2100 Sweden Dept of Rheumatology, University Hospital in Lund Lund, Sweden, 220 07 Iva Gunnarsson M.D. Stockholm, Sweden, 171 76 Lars Rönnblom M.D. Uppsala, Sweden, 751 85 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.85mL

0.57mL

0.29mL

14.27mL

2.85mL

1.43mL

28.54mL

5.71mL

2.85mL
参考文献

[1]Schelbergen RF, et al. Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74(12):2254-8.

[2]Tahvili S, et al. Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse. PLoS One. 2018 May 9;13(5):e0196598.

[3]Qirui Guo, et al. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. Cell Host Microbe. 2021 Feb 10;29(2):222-235.e4.